The University of Chicago Header Logo

Connection

Rita Nanda to Receptor, TIE-2

Back to Details
This is a "connection" page, showing publications Rita Nanda has written about Receptor, TIE-2.
Rita Nanda
Connection Strength
0.061
Receptor, TIE-2
  1. Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery. Clin Cancer Res. 2024 02 16; 30(4):729-740.
    View in: PubMed
    Score: 0.061
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.